During the past decade, Nalitt Cancer Institute at Staten Island University Hospital conducted 0 clinical trials. In the 10-year time frame, 0 clinical trials started and 12 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 4 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Nalitt Cancer Institute at Staten Island University Hospital" #1 sponsor was "Alliance for Clinical Trials in Oncology" with 6 trials, followed by "NSABP Foundation Inc" with 5 trials sponsored, "SWOG Cancer Research Network" with 2 trials sponsored, "ECOG-ACRIN Cancer Research Group" with 1 trials sponsored and "Eastern Cooperative Oncology Group" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Nalitt Cancer Institute at Staten Island University Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 16 trials as a collaborator, "SWOG Cancer Research Network" with 2 trials as a collaborator, "American College of Surgeons" with 1 trials as a collaborator, "Aptuit" with 1 trials as a collaborator and "Bristol-Myers Squibb" with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 7 trials.

According to Clinical.Site data, the most researched conditions in "Nalitt Cancer Institute at Staten Island University Hospital" are "Breast Cancer" (7 trials), "Colorectal Cancer" (3 trials), "Metastatic Cancer" (2 trials), "Pain" (2 trials) and "Breast Adenocarcinoma" (1 trials). Many other conditions were trialed in "Nalitt Cancer Institute at Staten Island University Hospital" in a lesser frequency.

Most popular intervention types in "Nalitt Cancer Institute at Staten Island University Hospital" are "Drug" (13 trials), "Other" (6 trials), "Biological" (4 trials), "Procedure" (3 trials) and "Radiation" (3 trials). Other intervention types were less common.

The name of intervention was led by "placebo" (4 trials), "bevacizumab" (2 trials), "cyclophosphamide" (2 trials), "radiation therapy" (2 trials) and "zoledronic acid" (2 trials). Other intervention names were less common.

The vast majority of trials in "Nalitt Cancer Institute at Staten Island University Hospital" are 9 trials for "All" genders, 6 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Nalitt Cancer Institute at Staten Island University Hospital". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in Nalitt Cancer Institute at Staten Island University Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Nalitt Cancer Institute at Staten Island University Hospital, 0 "Phase 1" clinical trials were conducted, 2 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".